U3 Pharma GmbH, based in Martinsried near Munich, Germany, is a leader in targeted cancer drug development. Established in July 2001, the company has produced a pipeline of novel targeted therapeutics based on the ground-breaking discoveries made by its founder - Professor Axel Ullrich.

Since May 2008, U3 Pharma has been an affiliate of  DAIICHI SANKYO Co. Ltd., one of the top 20 leading pharmaceutical companies worldwide and No. 3 in Japan. Being part of this global environment, U3 Pharma is striving to provide patients around the world with innovative antibody-based therapeutics.